Pharmacogenomics of Gynecological Disorders



Pharmacogenomics aims to identify the genome-based variability in drug disposition (metabolism and transport), which influences its efficacy and toxicity, and also to develop diagnostics and therapeutics on the basis of genetic variants so as individualize pharmacotherapy. Progress made in the last two decades in pharmacogenomics study of gynecological diseases has enabled us to predict the therapy outcome on the basis of inherited or acquired genetic mutations. The present chapter focuses on the clinical relevance of genetic variation in terms of diagnosis, prognosis, and therapeutics in context to this group of diseases with special reference to gynecological cancers. Various disease susceptibility genes and their polymorphisms of gynecological disorders have been identified, and their molecular diagnostics and targeted therapies developed. To name a few well studied are BRCA1/2, HER2, GSTT1, GSTM1, CYP1B1, PPAR-γ, VEGF, etc. Detailed account of the genetic components and their variants associated with each disease and how it influences the discourse of the disease and individualization of the therapy is given here.


Breast Cancer Vascular Endothelial Growth Factor Ovarian Cancer Cervical Cancer Endometrial Cancer 


  1. Aglund K, Rauvala M, Puistola U, Angstrom T, Turpeenniemi-Hujanen T, Zackrisson B, Stendahl U (2004) Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer-MMP-9 correlates to the grade and the stage. Gynecol Oncol 94:699–704PubMedGoogle Scholar
  2. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T (1986) The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232:1644–1646PubMedGoogle Scholar
  3. Ambrosone CB (2007) The promise and limitations of genome-wide association studies to elucidate the causes of breast cancer. Breast Cancer Res 9:114PubMedCentralPubMedGoogle Scholar
  4. Arngrimsson R, Hayward C, Nadaud S, Baldursdottir A, Walker JJ, Liston WA, Bjarnadottir RI, Brock DJ, Geirsson RT, Connor JM, Soubrier F (1997) Evidence for a familial pregnancy-induced hypertension locus in the eNOS-gene region. Am J Hum Genet 61:354–362PubMedCentralPubMedGoogle Scholar
  5. Arts HJ, Katsaros D, de Vries EG, Massobrio M, Genta F, Danese S, Arisio R, Scheper RJ, Kool M, Scheffer GL, Willemse PH, van der Zee AG, Suurmeijer AJ (1999) Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin Cancer Res 5:2798–2805PubMedGoogle Scholar
  6. Ashworth A (2008) A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26:3785–3790PubMedGoogle Scholar
  7. Ayoub N, Lucas C, Kaddoumi A (2011) Genomics and pharmacogenomics of breast cancer: current knowledge and trends. Asian Pac J Cancer Prev 12:1127–1140PubMedGoogle Scholar
  8. Badawi AF, Cavalieri EL, Rogan EG (2001) Role of human cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16alpha-hydroxylation of 17beta-estradiol. Metabolism 50:1001–1003PubMedGoogle Scholar
  9. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J (1998) Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58:2825–2831PubMedGoogle Scholar
  10. Baumwell S, Karumanchi SA (2007) Pre-eclampsia: clinical manifestations and molecular mechanisms. Nephron Clin Pract 106:c72–c81PubMedGoogle Scholar
  11. Bereketoglu C, Kasap M, Pazarbasi A (2012) Studies on Angiotensin-converting enzyme insertion/deletion polymorphism and genotype distributions in Turkish preeclampsia patients. J Pregnancy 2012:108206PubMedCentralPubMedGoogle Scholar
  12. Bogusiewicz M, Stryjecka-Zimmer M, Postawski K, Jakimiuk AJ, Rechberger T (2007) Activity of matrix metalloproteinase-2 and -9 and contents of their tissue inhibitors in uterine leiomyoma and corresponding myometrium. Gynecol Endocrinol 23:541–546PubMedGoogle Scholar
  13. Bombell S, McGuire W (2008) Tumour necrosis factor (-308A) polymorphism in pre-eclampsia: meta-analysis of 16 case-control studies. Aust N Z J Obstet Gynaecol 48:547–551PubMedGoogle Scholar
  14. Bosch TM, Huitema AD, Doodeman VD, Jansen R, Witteveen E, Smit WM, Jansen RL, van Herpen CM, Soesan M, Beijnen JH, Schellens JH (2006) Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res 12:5786–5793PubMedGoogle Scholar
  15. Broomall EM, Reynolds SM, Jacobson RM (2010) Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus. Postgrad Med 122:121–129PubMedGoogle Scholar
  16. Buchanan TA (2001) Pancreatic B-cell defects in gestational diabetes: implications for the pathogenesis and prevention of type 2 diabetes. J Clin Endocrinol Metab 86:989–993PubMedGoogle Scholar
  17. Calhoun ES, McGovern RM, Janney CA, Cerhan JR, Iturria SJ, Smith DI, Gostout BS, Persing DH (2002) Host genetic polymorphism analysis in cervical cancer. Clin Chem 48:1218–1224PubMedGoogle Scholar
  18. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638PubMedGoogle Scholar
  19. Cameron D, Casey M, Oliva C, Newstat B, Imwalle B, Geyer CE (2010) Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 15:924–934PubMedCentralPubMedGoogle Scholar
  20. Catalano PM, Tyzbir ED, Wolfe RR, Roman NM, Amini SB, Sims EA (1992) Longitudinal changes in basal hepatic glucose production and suppression during insulin infusion in normal pregnant women. Am J Obstet Gynecol 167:913–919PubMedGoogle Scholar
  21. Chatterjee K, Engelmark M, Gyllensten U, Dandara C, van der Merwe L, Galal U, Hoffman M, Williamson AL (2009) Fas and FasL gene polymorphisms are not associated with cervical cancer but differ among Black and Mixed-ancestry South Africans. BMC Res Notes 2:238PubMedCentralPubMedGoogle Scholar
  22. Chen ZP, Malapetsa A, Monks A, Myers TG, Mohr G, Sausville EA, Scudiero DA, Panasci LC (2002) Nucleotide excision repair protein levels vis-a-vis anticancer drug resistance in 60 human tumor cell lines. Ai Zheng 21:233–239PubMedGoogle Scholar
  23. Cho YM, Kim TH, Lim S, Choi SH, Shin HD, Lee HK, Park KS, Jang HC (2009) Type 2 diabetes-associated genetic variants discovered in the recent genome-wide association studies are related to gestational diabetes mellitus in the Korean population. Diabetologia 52:253–261PubMedGoogle Scholar
  24. Colacurci N, De Seta L, De Franciscis P, Mele D, Fortunato N, Cassese S (2000) Tamoxifen effects on endometrium. Panminerva Med 42:45–47PubMedGoogle Scholar
  25. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U et al (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132–1139PubMedGoogle Scholar
  26. Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM (2002) Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos 30:869–874PubMedGoogle Scholar
  27. Criscitiello C, Metzger-Filho O, Saini KS et al (2012) Targeted therapies in breast cancer: are heart and vessels also being targeted? Breast Cancer Res 14:209PubMedCentralPubMedGoogle Scholar
  28. Cui Z, Huang L (2005) Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer. Cancer Immunol Immunother 54:1180–1190PubMedGoogle Scholar
  29. Czernobilsky B, Lifschitz-Mercer B (1997) Endometrial pathology. Curr Opin Obstet Gynecol 9:52–56PubMedGoogle Scholar
  30. Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E (1992) ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84:1512–1517PubMedGoogle Scholar
  31. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E (1994) Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94:703–708PubMedCentralPubMedGoogle Scholar
  32. De Miranda J, Panizzutti R, Foltyn VN, Wolosker H (2002) Cofactors of serine racemase that physiologically stimulate the synthesis of the N-methyl-D-aspartate (NMDA) receptor coagonist D-serine. Proc Natl Acad Sci U S A 99:14542–14547PubMedCentralPubMedGoogle Scholar
  33. de Pace V, Chiossi G, Facchinetti F (2007) Clinical use of nitric oxide donors and L-arginine in obstetrics. J Matern Fetal Neonatal Med 20:569–579PubMedGoogle Scholar
  34. Dekker GA, Sibai BM (1998) Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol 179:1359–1375PubMedGoogle Scholar
  35. Delahanty RJ, Beeghly-Fadiel A, Xiang YB, Long J, Cai Q, Wen W, Xu WH, Cai H, He J, Gao YT, Zheng W, Shu XO (2011) Association of obesity-related genetic variants with endometrial cancer risk: a report from the Shanghai Endometrial Cancer Genetics Study. Am J Epidemiol 174:1115–1126PubMedCentralPubMedGoogle Scholar
  36. Di Nezza LA, Misajon A, Zhang J, Jobling T, Quinn MA, Ostor AG, Nie G, Lopata A, Salamonsen LA (2002) Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer 94:1466–1475PubMedGoogle Scholar
  37. Dileo J, Banerjee R, Whitmore M, Nayak JV, Falo LD Jr, Huang L (2003) Lipid-protamine-DNA-mediated antigen delivery to antigen-presenting cells results in enhanced anti-tumor immune responses. Mol Ther 7:640–648PubMedGoogle Scholar
  38. Doherty JA, Weiss NS, Freeman RJ, Dightman DA, Thornton PJ, Houck JR, Voigt LF, Rossing MA, Schwartz SM, Chen C (2005) Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev 14:357–366PubMedGoogle Scholar
  39. Dowsett M, Dunbier AK (2008) Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 14:8019–8026PubMedGoogle Scholar
  40. Duley L (2009) The global impact of pre-eclampsia and eclampsia. Semin Perinatol 33:130–137PubMedGoogle Scholar
  41. Eaton DL, Gallagher EP, Bammler TK, Kunze KL (1995) Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics 5:259–274PubMedGoogle Scholar
  42. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, Boyd J, Reis-Filho JS, Ashworth A (2008) Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451:1111–1115PubMedGoogle Scholar
  43. Evans JP, Skrzynia C, Burke W (2001) The complexities of predictive genetic testing. BMJ 322:1052–1056PubMedCentralPubMedGoogle Scholar
  44. Ferrara N, Vis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18:4–25PubMedGoogle Scholar
  45. Ferrara N, Houck K, Jakeman L, Leung DW (1992) Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 13:18–32PubMedGoogle Scholar
  46. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, Singh GM, Gutierrez HR, Lu Y, Bahalim AN, Farzadfar F, Riley LM, Ezzati M (2011) National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 377:557–567PubMedGoogle Scholar
  47. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, A'Hern R, Tutt A, Ashworth A, Stone J, Carmichael J, Schellens JH, de Bono JS, Kaye SB (2010) Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 28:2512–2519PubMedGoogle Scholar
  48. Franchim CS, Sass N, Mattar R, Pendeloski KP, Lin LH, Torloni MR, Daher S (2011) Inflammatory mediators gene polymorphisms in preeclampsia. Hypertens Pregnancy 30:338–346PubMedGoogle Scholar
  49. Freathy RM, Bennett AJ, Ring SM, Shields B, Groves CJ, Timpson NJ, Weedon MN, Zeggini E, Lindgren CM, Lango H, Perry JR, Pouta A, Ruokonen A, Hypponen E, Power C, Elliott P, Strachan DP, Jarvelin MR, Smith GD, McCarthy MI, Frayling TM, Hattersley AT (2009) Type 2 diabetes risk alleles are associated with reduced size at birth. Diabetes 58:1428–1433PubMedCentralPubMedGoogle Scholar
  50. Freathy RM, Hayes MG, Urbanek M, Lowe LP, Lee H, Ackerman C, Frayling TM, Cox NJ, Dunger DB, Dyer AR, Hattersley AT, Metzger BE, Lowe WL Jr (2010) Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study: common genetic variants in GCK and TCF7L2 are associated with fasting and postchallenge glucose levels in pregnancy and with the new consensus definition of gestational diabetes mellitus from the International Association of Diabetes and Pregnancy Study Groups. Diabetes 59:2682–2689PubMedCentralPubMedGoogle Scholar
  51. Freedman AN, Sansbury LB, Figg WD, Potosky AL, Weiss Smith SR, Khoury MJ, Nelson SA, Weinshilboum RM, Ratain MJ, McLeod HL, Epstein RS, Ginsburg GS, Schilsky RL, Liu G, Flockhart DA, Ulrich CM, Davis RL, Lesko LJ, Zineh I, Randhawa G, Ambrosone CB, Relling MV, Rothman N, Xie H, Spitz MR, Ballard-Barbash R, Doroshow JH, Minasian LM (2010) Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst 102:1698–1705PubMedCentralPubMedGoogle Scholar
  52. Gadducci A, Di Cristofano C, Zavaglia M, Giusti L, Menicagli M, Cosio S, Naccarato AG, Genazzani AR, Bevilacqua G, Cavazzana AO (2006) P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome. Anticancer Res 26:687–693PubMedGoogle Scholar
  53. Galic V, Willner J, Wollan M, Garg R, Garcia R, Goff BA, Gray HJ, Swisher EM (2007) Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas. Genes Chromosomes Cancer 46:239–247PubMedGoogle Scholar
  54. Garovic VD, Hayman SR (2007) Hypertension in pregnancy: an emerging risk factor for cardiovascular disease. Nat Clin Pract Nephrol 3:613–622PubMedGoogle Scholar
  55. Gelderman KA, Tomlinson S, Ross GD, Gorter A (2004) Complement function in mAb- mediated cancer immunotherapy. Trends Immunol 25:158–164PubMedGoogle Scholar
  56. Goetz MP, Suman VJ, Couch FJ, Ames MM, Rae JM, Erlander MG, Ma XJ, Sgroi DC, Reynolds CA, Lingle WL, Weinshilboum RM, Flockhart DA, Desta Z, Perez EA, Ingle JN (2008) Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance. Clin Cancer Res 14:5864–5868PubMedCentralPubMedGoogle Scholar
  57. Goldenberg RL, Culhane JF, Iams JD, Romero R (2008) Epidemiology and causes of preterm birth. Lancet 371:75–84PubMedGoogle Scholar
  58. Goodman MT, McDuffie K, Guo C, Terada K, Donlon TA (2001) CYP17 genotype and ovarian cancer: a null case-control study. Cancer Epidemiol Biomarkers Prev 10:563–564PubMedGoogle Scholar
  59. Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385–427PubMedGoogle Scholar
  60. Gradhand U, Kim RB (2008) Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2). Drug Metab Rev 40:317–354PubMedGoogle Scholar
  61. Graesslin O, Cortez A, Fauvet R, Lorenzato M, Birembaut P, Darai E (2006a) Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase-1 and -2 expression in normal, hyperplastic and neoplastic endometrium: a clinical-pathological correlation study. Ann Oncol 17:637–645PubMedGoogle Scholar
  62. Graesslin O, Cortez A, Uzan C, Birembaut P, Quereux C, Darai E (2006b) Endometrial tumor invasiveness is related to metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expressions. Int J Gynecol Cancer 16:1911–1917PubMedGoogle Scholar
  63. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, Helgason A, Stefansson H, Emilsson V, Helgadottir A, Styrkarsdottir U, Magnusson KP, Walters GB, Palsdottir E, Jonsdottir T, Gudmundsdottir T, Gylfason A, Saemundsdottir J, Wilensky RL, Reilly MP, Rader DJ, Bagger Y, Christiansen C, Gudnason V, Sigurdsson G, Thorsteinsdottir U, Gulcher JR, Kong A, Stefansson K (2006) Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 38:320–323PubMedGoogle Scholar
  64. Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C (2006) mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 12:854–859PubMedGoogle Scholar
  65. Green H, Soderkvist P, Rosenberg P, Mirghani RA, Rymark P, Lundqvist EA, Peterson C (2009) Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer. Basic Clin Pharmacol Toxicol 104:130–137PubMedGoogle Scholar
  66. Grenetier S, Bouchoux C, Goguel V (2006) CTD kinase I is required for the integrity of the rDNA tandem array. Nucleic Acids Res 34:4996–5006PubMedCentralPubMedGoogle Scholar
  67. Grimm SW, Dyroff MC (1997) Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase. Drug Metab Dispos 25:598–602PubMedGoogle Scholar
  68. Groenewoud MJ, Dekker JM, Fritsche A, Reiling E, Nijpels G, Heine RJ, Maassen JA, Machicao F, Schafer SA, Haring HU, t Hart LM, van Haeften TW (2008) Variants of CDKAL1 and IGF2BP2 affect first-phase insulin secretion during hyperglycaemic clamps. Diabetologia 51:1659–1663PubMedGoogle Scholar
  69. Hakli T, Romppanen EL, Hiltunen M, Helisalmi S, Punnonen K, Heinonen S (2003) Endothelial nitric oxide synthase polymorphism in preeclampsia. J Soc Gynecol Investig 10:154–157PubMedGoogle Scholar
  70. Hall JM, Lee MK (1990) Linkage of early onset familial breast cancer to chromosome 17q21. Science 250:1684–1689PubMedGoogle Scholar
  71. Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ, Sutter TR (1996) 17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc Natl Acad Sci U S A 93:9776–9781PubMedCentralPubMedGoogle Scholar
  72. Helgason A, Palsson S, Thorleifsson G, Grant SF, Emilsson V, Gunnarsdottir S, Adeyemo A, Chen Y, Chen G, Reynisdottir I, Benediktsson R, Hinney A, Hansen T, Andersen G, Borch-Johnsen K et al (2007) Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet 39:218–225PubMedGoogle Scholar
  73. Henderson BE, Feigelson HS (2000) Hormonal carcinogenesis. Carcinogenesis 21:427–433PubMedGoogle Scholar
  74. Henderson BE, Ross RK, Pike MC, Cassagrande JT (1982) Endogenous hormones as a major factor in human cancer. Cancer Res 24:3232–3239Google Scholar
  75. Henderson BE, Ross RK, Bernstein L (1988) Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 48:246PubMedGoogle Scholar
  76. Heubner M, Wimberger P, Riemann K, Kasimir-Bauer S, Otterbach F, Kimmig R, Siffert W (2010) The CYP1A1 Ile462Val polymorphism and platinum resistance of epithelial ovarian neoplasms. Oncol Res 18:343–347PubMedGoogle Scholar
  77. Hillermann R, Carelse K, Gebhardt GS (2005) The Glu298Asp variant of the endothelial nitric oxide synthase gene is associated with an increased risk for abruptio placentae in pre-eclampsia. J Hum Genet 50:415–419PubMedGoogle Scholar
  78. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97:3473–3478PubMedCentralPubMedGoogle Scholar
  79. Hunter KW et al (2001) Predisposition to efficient mammary tumor metastatic progression is linked to the breast cancer metastasis suppressor gene Brms1. Cancer Res 61:8866–8872PubMedGoogle Scholar
  80. Hurvitz SA, Pegram MD, Lin L-S, Chan DS, Allen HJ, Dichmann RA, Hagenstad CT, Barstis J, Hermann RC, Hu EH, Moroose RL, Thomas SP, Vogel CL, Ryba N, Elashoff D (2009) Final results of a phase II trial evaluating trastuzumab and bevacizumab as first line treatment of HER2-amplified advanced breast cancer. Cancer Res 69:854Google Scholar
  81. Indermaur MD, Xiong Y, Kamath SG, Boren T, Hakam A, Wenham RM, Apte SM, Lancaster JM (2010) Genomic-directed targeted therapy increases endometrial cancer cell sensitivity to doxorubicin. Am J Obstet Gynecol 203:158.e1–158.e40Google Scholar
  82. Ingle JN, Suman VJ (2005) Aromatase inhibitors for therapy of advanced breast cancer. J Steroid Biochem Mol Biol 95:113–119PubMedGoogle Scholar
  83. Ingle JN, Suman VJ, Rowland KM, Mirchandani D, Bernath AM, Camoriano JK, Fishkin PA, Nikcevich DA, Perez EA (2006) Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol 24:1052–1056PubMedGoogle Scholar
  84. Ingle JN, Tu D, Pater JL, Muss HB, Martino S, Robert NJ, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE (2008) Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol 19:877–882PubMedGoogle Scholar
  85. Irani RA, Xia Y (2008) The functional role of the renin-angiotensin system in pregnancy and preeclampsia. Placenta 29:763–771PubMedCentralPubMedGoogle Scholar
  86. Isaka K, Nishi H, Nakai H, Nakada T, Feng Li Y, Ebihara Y, Takayama M (2003) Matrix metalloproteinase-26 is expressed in human endometrium but not in endometrial carcinoma. Cancer 97:79–89PubMedGoogle Scholar
  87. Ishigami T, Tamura K, Fujita T, Kobayashi I, Hibi K, Kihara M, Toya Y, Ochiai H, Umemura S (1999) Angiotensinogen gene polymorphism near transcription start site and blood pressure: role of a T-to-C transition at intron I. Hypertension 34:430–434PubMedGoogle Scholar
  88. Itamochi H, Kigawa J, Sultana H, Iba T, Akeshima R, Kamazawa S, Kanamori Y, Terakawa N (2002) Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary. Jpn J Cancer Res 93:723–728PubMedGoogle Scholar
  89. Ito K (2007) Hormone replacement therapy and cancers: the biological roles of estrogen and progestin in tumorigenesis are different between the endometrium and breast. Tohoku J Exp Med 212:1–12PubMedGoogle Scholar
  90. Ji LD, Zhang LN, Shen P, Wang P, Zhang YM, Xing WH, Xu J (2010) Association of angiotensinogen gene M235T and angiotensin-converting enzyme gene I/D polymorphisms with essential hypertension in Han Chinese population: a meta-analysis. J Hypertens 28:419–428PubMedGoogle Scholar
  91. Kamazawa S, Kigawa J, Kanamori Y, Itamochi H, Sato S, Iba T, Terakawa N (2002) Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol Oncol 86:171–176PubMedGoogle Scholar
  92. Kang S, Ju W, Kim JW, Park NH, Song YS, Kim SC, Park SY, Kang SB, Lee HP (2006) Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. Exp Mol Med 38:320–324PubMedGoogle Scholar
  93. Karahan N, Guney M, Baspinar S, Oral B, Kapucuoglu N, Mungan T (2007) Expression of gelatinase (MMP-2 and MMP-9) and cyclooxygenase-2 (COX-2) in endometrial carcinoma. Eur J Gynaecol Oncol 28:184–188PubMedGoogle Scholar
  94. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H, Chambon P (1990) Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 9:1603–1614PubMedCentralPubMedGoogle Scholar
  95. Kautzky-Willer A, Prager R, Waldhausl W, Pacini G, Thomaseth K, Wagner OF, Ulm M, Streli C, Ludvik B (1997) Pronounced insulin resistance and inadequate beta-cell secretion characterize lean gestational diabetes during and after pregnancy. Diabetes Care 20:1717–1723PubMedGoogle Scholar
  96. Khrunin A, Ivanova F, Moisseev A, Khokhrin D, Sleptsova Y, Gorbunova V, Limborska S (2012) Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins. Pharmacogenomics 13:171–178PubMedGoogle Scholar
  97. Kim S, Misra A (2007) SNP genotyping: technologies and biomedical applications. Annu Rev Biomed Eng 9:289–320PubMedGoogle Scholar
  98. Kim YJ, Park BH, Park H, Jung SC, Pang MG, Ryu HM, Lee KS, Eom SM, Park HY (2008) No association of the genetic polymorphisms of endothelial nitric oxide synthase, dimethylarginine dimethylaminohydrolase, and vascular endothelial growth factor with preeclampsia in Korean populations. Twin Res Hum Genet 11:77–83PubMedGoogle Scholar
  99. Kim JY, Cheong HS, Park BL, Baik SH, Park S, Lee SW, Kim MH, Chung JH, Choi JS, Kim MY, Yang JH, Cho DH, Shin HD, Kim SH (2011) Melatonin receptor 1 B polymorphisms associated with the risk of gestational diabetes mellitus. BMC Med Genet 12:82PubMedCentralPubMedGoogle Scholar
  100. King CR, Kraus MH, Aaronson SA (1985) Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229:974–976PubMedGoogle Scholar
  101. Kiyohara C, Nakanishi Y, Inutsuka S, Takayama K, Hara N, Motohiro A, Tanaka K, Kono S, Hirohata T (1998) The relationship between CYP1A1 aryl hydrocarbon hydroxylase activity and lung cancer in a Japanese population. Pharmacogenetics 8:315–323PubMedGoogle Scholar
  102. Kleinbongard P, Dejam A, Lauer T, Rassaf T, Schindler A, Picker O, Scheeren T, Godecke A, Schrader J, Schulz R, Heusch G, Schaub GA, Bryan NS, Feelisch M, Kelm M (2003) Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals. Free Radic Biol Med 35:790–796PubMedGoogle Scholar
  103. Konecny G, Untch M, Pegram M (1999) Herceptin in the treatment of metastatic breast cancer. Gynäkolog 32:624–631Google Scholar
  104. Konig M, Shuldiner AR (2012) The genetic interface between gestational diabetes and type 2 diabetes. J Matern Fetal Neonatal Med 25:36–40PubMedGoogle Scholar
  105. Kristensen VN, Harada N, Yoshimura N, Haraldsen E, Lonning PE, Erikstein B, Karesen R, Kristensen T, Borresen-Dale AL (2000) Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene 19:1329–1333PubMedGoogle Scholar
  106. Kuhl C (1991) Aetiology of gestational diabetes. Baillieres Clin Obstet Gynaecol 5:279–292PubMedGoogle Scholar
  107. Kupferminc MJ (2005) Thrombophilia and pregnancy. Curr Pharm Des 11:735–748PubMedGoogle Scholar
  108. Kwak SH, Kim SH, Cho YM, Go MJ, Cho YS, Choi SH, Moon MK, Jung HS, Shin HD, Kang HM, Cho NH, Lee IK, Kim SY, Han BG, Jang HC, Park KS (2012) A genome-wide association study of gestational diabetes mellitus in Korean women. Diabetes 61:531–541PubMedCentralPubMedGoogle Scholar
  109. Laird SM, Dalton CF, Okon MA, Bunning RA, Marshall R, Li TC (1999) Metalloproteinases and tissue inhibitor of metalloproteinase 1 (TIMP-1) in endometrial flushings from pre- and post-menopausal women and from women with endometrial adenocarcinoma. J Reprod Fertil 115:225–232PubMedGoogle Scholar
  110. LaMarca BD, Ryan MJ, Gilbert JS, Murphy SR, Granger JP (2007) Inflammatory cytokines in the pathophysiology of hypertension during preeclampsia. Curr Hypertens Rep 9:480–485PubMedGoogle Scholar
  111. Lapolla A, Dalfra MG, Fedele D (2009) Diabetes related autoimmunity in gestational diabetes mellitus: is it important? Nutr Metab Cardiovasc Dis 19:674–682PubMedGoogle Scholar
  112. Lauenborg J, Grarup N, Damm P, Borch-Johnsen K, Jorgensen T, Pedersen O, Hansen T (2009) Common type 2 diabetes risk gene variants associate with gestational diabetes. J Clin Endocrinol Metab 94:145–150PubMedGoogle Scholar
  113. Lee W, Lockhart AC, Kim RB, Rothenberg ML (2005) Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist 10:104–111PubMedGoogle Scholar
  114. Lee E, Hsu C, Haiman CA, Razavi P, Horn-Ross PL, Van Den Berg D, Bernstein L, Le Marchand L, Henderson BE, Setiawan VW, Ursin G (2010) Genetic variation in the progesterone receptor gene and risk of endometrial cancer: a haplotype-based approach. Carcinogenesis 31:1392–1399PubMedCentralPubMedGoogle Scholar
  115. Levesque S, Moutquin JM, Lindsay C, Roy MC, Rousseau F (2004) Implication of an AGT haplotype in a multigene association study with pregnancy hypertension. Hypertension 43:71–78PubMedGoogle Scholar
  116. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K (2000) Environmental and heritable factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343:78–85PubMedGoogle Scholar
  117. Liehr JG, Ricci MJ, Jefcoate CR, Hannigan EV, Hokanson JA, Zhu BT (1995) 4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: implications for the mechanism of uterine tumorigenesis. Proc Natl Acad Sci U S A 92:9220–9224PubMedCentralPubMedGoogle Scholar
  118. Lin R, Lei Y, Yuan Z, Ju H, Li D (2012) Angiotensinogen gene M235T and T174M polymorphisms and susceptibility of pre-eclampsia: a meta-analysis. Ann Hum Genet 76:377–386PubMedGoogle Scholar
  119. Lindheimer MD, Taler SJ, Cunningham FG (2010) Hypertension in pregnancy. J Am Soc Hypertens 4:68–78PubMedGoogle Scholar
  120. Lundberg JO, Weitzberg E, Gladwin MT (2008) The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov 7:156–167PubMedGoogle Scholar
  121. Martin CM, Kehoe L, Spillane CO, O'Leary JJ (2007) Gene discovery in cervical cancer: towards diagnostic and therapeutic biomarkers. Mol Diagn Ther 11:277–290PubMedGoogle Scholar
  122. Marzolini C, Paus E, Buclin T, Kim RB (2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75:13–33PubMedGoogle Scholar
  123. McGrath M, Hankinson SE, Arbeitman L, Colditz GA, Hunter DJ, De Vivo I (2004) Cytochrome P450 1B1 and catechol-O-methyltransferase polymorphisms and endometrial cancer susceptibility. Carcinogenesis 25:559–565PubMedGoogle Scholar
  124. Medeiros R, Pereira D, Afonso N, Palmeira C, Faleiro C, Afonso-Lopes C, Freitas-Silva M, Vasconcelos A, Costa S, Osorio T, Lopes C (2003) Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome. Int J Clin Oncol 8:156–161PubMedGoogle Scholar
  125. Meehan KL, Rainczuk A, Salamonsen LA, Stephens AN (2010) Proteomics and the search for biomarkers of female reproductive diseases. Reproduction 140:505–519PubMedGoogle Scholar
  126. Meekins JW, Pijnenborg R, Hanssens M, McFadyen IR, van Asshe A (1994) A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol 101:669–674PubMedGoogle Scholar
  127. Metzger IF, Souza-Costa DC, Marroni AS, Nagassaki S, Desta Z, Flockhart DA, Tanus-Santos JE (2005) Endothelial nitric oxide synthase gene haplotypes associated with circulating concentrations of nitric oxide products in healthy men. Pharmacogenet Genomics 15:565–570PubMedGoogle Scholar
  128. Metzger IF, Sertorio JT, Tanus-Santos JE (2007) Modulation of nitric oxide formation by endothelial nitric oxide synthase gene haplotypes. Free Radic Biol Med 43:987–992PubMedGoogle Scholar
  129. Middeldorp S (2007) Pregnancy failure and heritable thrombophilia. Semin Hematol 44:93–97PubMedGoogle Scholar
  130. Mikhailova ON, Gulyaeva LF, Prudnikov AV, Gerasimov AV, Krasilnikov SE (2006) Estrogen-metabolizing gene polymorphisms in the assessment of female hormone-dependent cancer risk. Pharmacogenomics J 6:189–193PubMedGoogle Scholar
  131. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cichran C, Bennett LM, Ding W et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71PubMedGoogle Scholar
  132. Milano G, Etienne MC (1994) Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil (review). Anticancer Res 14:2295–2297PubMedGoogle Scholar
  133. Milano G, Etienne MC, Pierrefite V et al (1999) Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 79:627–630PubMedCentralPubMedGoogle Scholar
  134. Misugi F, Sumi T, Okamoto E, Nobeyama H, Hattori K, Yoshida H, Matsumoto Y, Yasui T, Honda K, Ishiko O (2005) Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in uterine endometrial carcinoma and a correlation between expression of matrix metalloproteinase-7 and prognosis. Int J Mol Med 16:541–546PubMedGoogle Scholar
  135. Modugno F, Weissfeld JL, Trump DL, Zmuda JM, Shea P, Cauley JA, Ferrell RE (2001) Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk. Clin Cancer Res 7:3092–3096PubMedGoogle Scholar
  136. Monaghan H, MacWhinnie N, Williams AR (2007) The role of matrix metalloproteinases-2, -7 and -9 and beta-catenin in high grade endometrial carcinoma. Histopathology 50:348–357PubMedGoogle Scholar
  137. Moreno-Bueno G, Sanchez-Estevez C, Cassia R, Rodriguez-Perales S, Diaz-Uriarte R, Dominguez O, Hardisson D, Andujar M, Prat J, Matias-Guiu X, Cigudosa JC, Palacios J (2003) Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res 63:5697–5702PubMedGoogle Scholar
  138. Myatt L, Webster RP (2009) Vascular biology of preeclampsia. J Thromb Haemost 7:375–384PubMedGoogle Scholar
  139. Napolitano M, Miceli F, Calce A, Vacca A, Gulino A, Apa R, Lanzone A (2000) Expression and relationship between endothelin-1 messenger ribonucleic acid (mRNA) and inducible/endothelial nitric oxide synthase mRNA isoforms from normal and preeclamptic placentas. J Clin Endocrinol Metab 85:2318–2323PubMedGoogle Scholar
  140. Nishioka Y, Kobayashi K, Sagae S, Ishioka S, Nishikawa A, Matsushima M, Kanamori Y, Minaguchi T, Nakamura Y, Tokino T, Kudo R (2000) A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter in endometrial carcinomas. Japanese J Cancer Res 91:612–615Google Scholar
  141. Nunobiki O, Ueda M, Toji E, Yamamoto M, Akashi K, Sato N et al (2011) Genetic polymorphism of cancer susceptibility genes and HPV infection in cervical carcinogenesis. Pathol Res Int 2011:364069Google Scholar
  142. Obata H, Yahata T, Quan J, Sekine M, Tanaka K (2006) Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer. Anticancer Res 26:2227–2232PubMedGoogle Scholar
  143. O’Brien C, Cavet G, Pandita A, Hu X, Haydu L, Mohan S, Toy K, Rivers CS, Modrusan Z, Amler LC, Lackner MR (2008) Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer. Cancer Res 68:5380–5389PubMedGoogle Scholar
  144. Olopade OI, Grushko TA, Nanda R, Huo D (2008) Advances in breast cancer: pathways to personalized medicine. Clin Cancer Res 14:7988–7999PubMedGoogle Scholar
  145. O’Mara TA, Clements JA, Spurdle AB (2009) The use of predictive or prognostic genetic biomarkers in endometrial and other hormone-related cancers: justification for extensive candidate gene single nucleotide polymorphism studies of the matrix metalloproteinase family and their inhibitors. Cancer Epidemiol Biomarkers Prev 18:2352–2365PubMedGoogle Scholar
  146. O’Mara TA, Fahey P, Ferguson K, Marquart L, Lambrechts D, Despierre E, Vergote I, Amant F, Hall P, Liu J, Czene K, Rebbeck TR, Ahmed S, Dunning AM, Gregory CS, Shah M, Webb PM, Spurdle AB (2011) Progesterone receptor gene variants and risk of endometrial cancer. Carcinogenesis 32:331–335PubMedCentralPubMedGoogle Scholar
  147. Osborne CK, Wiebe VJ, McGuire WL, Ciocca DR, DeGregorio MW (1992) Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients. J Clin Oncol 10:304–310PubMedGoogle Scholar
  148. Papadopoulou A, Lynch KF, Shaat N, Hakansson R, Ivarsson SA, Berntorp K, Agardh CD, Lernmark A (2011) Gestational diabetes mellitus is associated with TCF7L2 gene polymorphisms independent of HLA-DQB1*0602 genotypes and islet cell autoantibodies. Diabet Med 28:1018–1027PubMedCentralPubMedGoogle Scholar
  149. Papanicolaou GN (1942) A new procedure for staining vaginal smears. Science 95:438–439PubMedGoogle Scholar
  150. Papazoglou D, Galazios G, Koukourakis MI, Panagopoulos I, Kontomanolis EN, Papatheodorou K, Maltezos E (2004) Vascular endothelial growth factor gene polymorphisms and pre-eclampsia. Mol Hum Reprod 10:321–324PubMedGoogle Scholar
  151. Pappa KI, Gazouli M, Economou K, Daskalakis G, Anastasiou E, Anagnou NP, Antsaklis A (2011) Gestational diabetes mellitus shares polymorphisms of genes associated with insulin resistance and type 2 diabetes in the Greek population. Gynecol Endocrinol 27:267–272PubMedGoogle Scholar
  152. Park YG, Zhao X, Lesueur F, Lowy DR, Lancaster M, Pharoah P, Qian X, Hunter KW (2005) Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nat Genet 37:1055–1062PubMedCentralPubMedGoogle Scholar
  153. Paynter RA, Hankinson SE, Colditz GA, Hunter DJ, De Vivo I (2004) No evidence of a role for PPAR gamma Pro12Ala polymorphism in endometrial cancer susceptibility. Pharmacogenetics 14:851–856PubMedGoogle Scholar
  154. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D (1999) Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18:2241–2251PubMedGoogle Scholar
  155. Penson RT, Oliva E, Skates SJ, Glyptis T, Fuller AF Jr, Goodman A, Seiden MV (2004) Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol 93:98–106PubMedGoogle Scholar
  156. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359:572–577PubMedGoogle Scholar
  157. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ (1994) Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9:1829–1838PubMedGoogle Scholar
  158. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ (1995) HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435–2446PubMedGoogle Scholar
  159. Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ (1998) Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17:2235–2249PubMedGoogle Scholar
  160. Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ (1999) Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 59:1347–1355PubMedGoogle Scholar
  161. Pitot HC, Loeb DD (2002) Fundamentals of oncology, 4th edn. Marcel Dekker Publisher/Informa Healthcare, New YorkGoogle Scholar
  162. Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R et al (1993) Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 53:4960–4970PubMedGoogle Scholar
  163. Raftogianis RB, Wood TC, Otterness DM, Van Loon JA, Weinshilboum RM (1997) Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype. Biochem Biophys Res Commun 239:298–304PubMedGoogle Scholar
  164. Raftogianis R, Creveling C, Weinshilboum R, Weisz J (2000) Estrogen metabolism by conjugation. J Natl Cancer Inst Monogr 27:113–124Google Scholar
  165. Rahimi Z, Mozafari H, Parsian A (2013) Preeclampsia and angiotensin converting enzyme (ACE) I/D and angiotensin II type-1 receptor (AT1R) A1166C polymorphisms: association with ACE I/D polymorphism. J Renin Angiotensin Aldosterone Syst 14:174–180Google Scholar
  166. Ravdin PM, Chamness GC (1995) The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers–a review. Gene 159:19–27PubMedGoogle Scholar
  167. Rebbeck TR (1997) Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 6:733–743PubMedGoogle Scholar
  168. Rebbeck TR, Troxel AB, Norman S, Bunin G, DeMichele A, Schinnar R, Berlin JA, Strom BL (2007) Pharmacogenetic modulation of combined hormone replacement therapy by progesterone-metabolism genotypes in postmenopausal breast cancer risk. Am J Epidemiol 166:1392–1399PubMedGoogle Scholar
  169. Rehman I, Cross SS, Azzouzi AR, Catto JW, Deloulme JC, Larre S, Champigneuille J, Fromont G, Cussenot O, Hamdy FC (2004) S100A6 (Calcyclin) is a prostate basal cell marker absent in prostate cancer and its precursors. Br J Cancer 91:739–744PubMedCentralPubMedGoogle Scholar
  170. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E (2000) A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 37:443–448PubMedGoogle Scholar
  171. Rieck S, Kaestner KH (2010) Expansion of beta-cell mass in response to pregnancy. Trends Endocrinol Metab 21:151–158PubMedCentralPubMedGoogle Scholar
  172. Rutter JL, Mitchell TI, Buttice G, Meyers J, Gusella JF, Ozelius LJ, Brinckerhoff CE (1998) A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 58:5321–5325PubMedGoogle Scholar
  173. Rylander-Rudqvist T, Wedren S, Jonasdottir G, Ahlberg S, Weiderpass E, Persson I, Ingelman-Sundberg M (2004) Cytochrome P450 1B1 gene polymorphisms and postmenopausal endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 13:1515–1520PubMedGoogle Scholar
  174. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, Urban N, Taniguchi T (2008) Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451:1116–1120PubMedCentralPubMedGoogle Scholar
  175. Sakai W, Swisher EM, Jacquemont C, Chandramohan KV, Couch FJ, Langdon SP, Wurz K, Higgins J, Villegas E, Taniguchi T (2009) Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res 69:6381–6386PubMedCentralPubMedGoogle Scholar
  176. Saldivar JS, Lu KH, Liang D, Gu J, Huang M, Vlastos AT, Follen M, Wu X (2007) Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients. Gynecol Oncol 107:S223–S229PubMedGoogle Scholar
  177. Sampath D, Greenberger LM, Beyer C, Hari M, Liu H, Baxter M, Yang S, Rios C, Discafani C (2006) Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models. Clin Cancer Res 12:3459–3469PubMedGoogle Scholar
  178. Sandrim VC, de Syllos RW, Lisboa HR, Tres GS, Tanus-Santos JE (2007) Influence of eNOS haplotypes on the plasma nitric oxide products concentrations in hypertensive and type 2 diabetes mellitus patients. Nitric Oxide 16:348–355PubMedGoogle Scholar
  179. Sandrim VC, Palei AC, Sertorio JT, Cavalli RC, Duarte G, Tanus-Santos JE (2010) Effects of eNOS polymorphisms on nitric oxide formation in healthy pregnancy and in pre-eclampsia. Mol Hum Reprod 16:506–510PubMedGoogle Scholar
  180. Sarah R, Esther NM, Shaker A (2010) Mousa Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management. Pharmacogenomics Pers Med 3:129–143Google Scholar
  181. Sasaki M, Tanaka Y, Kaneuchi M, Sakuragi N, Dahiya R (2003) CYP1B1 gene polymorphisms have higher risk for endometrial cancer, and positive correlations with estrogen receptor alpha and estrogen receptor beta expressions. Cancer Res 63:3913–3918PubMedGoogle Scholar
  182. Schouten LJ, Goldbohm RA, van den Brandt PA (2004) Anthropometry, physical activity, and endometrial cancer risk: results from the Netherlands Cohort Study. J Natl Cancer Inst 96:1635–1638PubMedGoogle Scholar
  183. Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, Simon W, Eichelbaum M, Brauch H (2007) Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25:5187–5519PubMedGoogle Scholar
  184. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Bolander J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M, Brauch H (2009) Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302:1429–1436PubMedGoogle Scholar
  185. Scott LJ, Bonnycastle LL, Willer CJ, Sprau AG, Jackson AU, Narisu N, Duren WL, Chines PS, Stringham HM, Erdos MR et al (2006) Association of transcription factor 7-like 2 (TCF7L2) variants with type 2 diabetes in a Finnish sample. Diabetes 55:2649–2653PubMedGoogle Scholar
  186. Seraj MJ, Samant RS, Verderame MF, Welch DR (2000) Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Res 60:2764–2769PubMedGoogle Scholar
  187. Seremak-Mrozikiewicz A, Drews K, Barlik M, Sieroszewski P, Grzeskowiak E, Mrozikiewicz P (2011) The significance of -786T > C polymorphism of endothelial NO synthase (eNOS) gene in severe preeclampsia. J Matern Fetal Neonatal Med 24:432–436PubMedGoogle Scholar
  188. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P (1993) Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 11:1936–1942PubMedGoogle Scholar
  189. Sethi AA, Nordestgaard BG, Tybjaerg-Hansen A (2003) Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: a meta-analysis. Arterioscler Thromb Vasc Biol 23:1269–1275PubMedGoogle Scholar
  190. Shaat N, Lernmark A, Karlsson E, Ivarsson S, Parikh H, Berntorp K, Groop L (2007) A variant in the transcription factor 7-like 2 (TCF7L2) gene is associated with an increased risk of gestational diabetes mellitus. Diabetologia 50:972–979PubMedGoogle Scholar
  191. Shah DM (2006) The role of RAS in the pathogenesis of preeclampsia. Curr Hypertens Rep 8:144–152PubMedGoogle Scholar
  192. Sharma M, Shubert DE, Lewis J, McGarrigle BP, Bofinger DP, Olson JR (2003) Biotransformation of tamoxifen in a human endometrial explant culture model. Chem Biol Interact 146:237–249PubMedGoogle Scholar
  193. Shepard HM, Lewis GD, Sarup JC, Fendly BM, Maneval D, Mordenti J, Figari I, Kotts CE, Palladino MA Jr, Ullrich A et al (1991) Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol 11:117–127PubMedGoogle Scholar
  194. Shim JY, Jun JK, Jung BK, Kim SH, Won HS, Lee PR, Kim A (2007) Vascular endothelial growth factor gene +936 C/T polymorphism is associated with preeclampsia in Korean women. Am J Obstet Gynecol 197(271):e271–e274Google Scholar
  195. Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM, Graham-Lorence S, Amarneh B, Ito Y, Fisher CR, Michael MD et al (1994) Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 15:342–355PubMedGoogle Scholar
  196. Sissung TM, Price DK, Sparreboom A, Figg WD (2006) Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Mol Cancer Res 4:135–150PubMedGoogle Scholar
  197. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182PubMedGoogle Scholar
  198. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712PubMedGoogle Scholar
  199. Smith GC, Pell JP, Walsh D (2001) Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births. Lancet 357:2002–2006PubMedGoogle Scholar
  200. Soini Y, Alarakkola E, Autio-Harmainen H (1997) Expression of messenger RNAs for metalloproteinases 2 and 9, type IV collagen, and laminin in nonneoplastic and neoplastic endometrium. Hum Pathol 28:220–226PubMedGoogle Scholar
  201. Stearns V, Davidson NE, Flockhart DA (2004) Pharmacogenetics in the treatment of breast cancer. Pharmacogenomics J 4:143–153PubMedGoogle Scholar
  202. Steffensen KD, Waldstrom M, Brandslund I, Jakobsen A (2010) The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol 117:109–116PubMedGoogle Scholar
  203. Steinthorsdottir V, Thorleifsson G, Reynisdottir I, Benediktsson R, Jonsdottir T, Walters GB, Styrkarsdottir U, Gretarsdottir S, Emilsson V, Ghosh S, Baker A, Snorradottir S, Bjarnason H, Ng MC, Hansen T, Bagger Y, Wilensky RL, Reilly MP, Adeyemo A, Chen Y, Zhou J, Gudnason V, Chen G, Huang H, Lashley K, Doumatey A, So WY, Ma RC, Andersen G, Borch-Johnsen K, Jorgensen T, van Vliet-Ostaptchouk JV, Hofker MH, Wijmenga C, Christiansen C, Rader DJ, Rotimi C, Gurney M, Chan JC, Pedersen O, Sigurdsson G, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K (2007) A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet 39:770–775PubMedGoogle Scholar
  204. Stephens M, Smith NJ, Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978–989PubMedCentralPubMedGoogle Scholar
  205. Sugimoto M, Yoshida S, Kennedy S, Deguchi M, Ohara N, Maruo T (2006) Matrix metalloproteinase-1 and -9 promoter polymorphisms and endometrial carcinoma risk in a Japanese population. J Soc Gynecol Investig 13:523–529PubMedGoogle Scholar
  206. Suspitsin EN, Grigoriev MY, Togo AV, Kuligina ES, Belogubova EV, Pozharisski KM, Chagunava OL, Sokolov EP, Theillet C, Berstein LM, Hanson KP, Imyanitov EN (2002) Distinct prevalence of the CYP19 Delta3(TTTA)(7) allele in premenopausal versus postmenopausal breast cancer patients, but not in control individuals. Eur J Cancer 38:1911–1916PubMedGoogle Scholar
  207. Takemura M, Azuma C, Kimura T, Tokugawa Y, Miki M, Ono M, Saji F, Tanizawa O (1992) Malignant cell-specific gelatinase activity in human endometrial carcinoma. Cancer 70:147–151PubMedGoogle Scholar
  208. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S, Terakawa N, Otsubo K (2001) Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297:1137–1143PubMedGoogle Scholar
  209. Tanaka Y, Sasaki M, Kaneuchi M, Shiina H, Igawa M, Dahiya R (2002) Polymorphisms of the CYP1B1 gene have higher risk for prostate cancer. Biochem Biophys Res Commun 296:820–826PubMedGoogle Scholar
  210. Tong D, Fabjani G, Heinze G, Obermair A, Leodolter S, Zeillinger R (2001) Analysis of the human progesterone receptor gene polymorphism progins in Austrian ovarian carcinoma patients. Int J Cancer 95:394–397PubMedGoogle Scholar
  211. Tong Y, Lin Y, Zhang Y, Yang J, Liu H, Zhang B (2009) Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: a large Human Genome Epidemiology (HuGE) review and meta-analysis. BMC Med Genet 10:15PubMedCentralPubMedGoogle Scholar
  212. Tran A, Jullien V, Alexandre J, Rey E, Rabillon F, Girre V, Dieras V, Pons G, Goldwasser F, Treluyer JM (2006) Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 79:570–580PubMedGoogle Scholar
  213. Tunuguntla R, Ripley D, Sang QX, Chegini N (2003) Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinases TIMP-3 and -4 in benign endometrium and endometrial cancer. Gynecol Oncol 89:453–459PubMedGoogle Scholar
  214. Ubeda M, Rukstalis JM, Habener JF (2006) Inhibition of cyclin-dependent kinase 5 activity protects pancreatic beta cells from glucotoxicity. J Biol Chem 281:28858–28864PubMedGoogle Scholar
  215. Ueda M, Hung YC, Terai Y, Kanda K, Takehara M, Yamashita H, Yamaguchi H, Akise D, Yasuda M, Nishiyama K, Ueki M (2003) Glutathione S-transferase GSTM1, GSTT1 and p53 codon 72 polymorphisms in human tumor cells. Hum Cell 16:241–251PubMedGoogle Scholar
  216. Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE (2001) Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 22:195–201PubMedGoogle Scholar
  217. Ueno H, Yamashita K, Azumano I, Inoue M, Okada Y (1999) Enhanced production and activation of matrix metalloproteinase-7 (matrilysin) in human endometrial carcinomas. Int J Cancer 84:470–477PubMedGoogle Scholar
  218. Valabrega G, Montemurro F, Aglietta M (2007) Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 18:977–984PubMedGoogle Scholar
  219. Vella N, Aiello M, Russo AE, Scalisi A, Spandidos DA, Toffoli G, Sorio R, Libra M, Stivala F (2004) ‘Genetic profiling’ and ovarian cancer therapy. Mol Med Rep 4:771–777Google Scholar
  220. Velloso EP, Vieira R, Cabral AC, Kalapothakis E, Santos RA (2007) Reduced plasma levels of angiotensin-(1-7) and renin activity in preeclamptic patients are associated with the angiotensin I- converting enzyme deletion/deletion genotype. Braz J Med Biol Res 40:583–590PubMedGoogle Scholar
  221. Vitoratos N, Hassiakos D, Iavazzo C (2012) Molecular mechanisms of preeclampsia. J Pregnancy 2012:298343PubMedCentralPubMedGoogle Scholar
  222. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719–726PubMedGoogle Scholar
  223. Wang Y, Nie M, Li W, Ping F, Hu Y, Ma L, Gao J, Liu J (2011) Association of six single nucleotide polymorphisms with gestational diabetes mellitus in a Chinese population. PLoS One 6:e26953PubMedCentralPubMedGoogle Scholar
  224. Watanabe RM, Allayee H, Xiang AH, Trigo E, Hartiala J, Lawrence JM, Buchanan TA (2007) Transcription factor 7-like 2 (TCF7L2) is associated with gestational diabetes mellitus and interacts with adiposity to alter insulin secretion in Mexican Americans. Diabetes 56:1481–1485PubMedCentralPubMedGoogle Scholar
  225. Widschwendter M, Siegmund KD, Muller HM, Fiegl H, Marth C, Muller-Holzner E, Jones PA, Laird PW (2004) Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 64:3807–3813PubMedGoogle Scholar
  226. Williams-Jones B, Corrigan OP (2003) Rhetoric and hype: where’s the ‘ethics’ in pharmacogenomics? Am J Pharmacogenomics 3:375–383PubMedGoogle Scholar
  227. Xie F, Hu Y, Speert DP, Turvey SE, Peng G, Money DM, Magee LA, von Dadelszen P (2010) Toll-like receptor gene polymorphisms and preeclampsia risk: a case-control study and data synthesis. Hypertens Pregnancy 29:390–398PubMedGoogle Scholar
  228. Xu X, Duncan AM, Merz-Demlow BE, Phipps WR, Kurzer MS (1999) Menstrual cycle effects on urinary estrogen metabolites. J Clin Endocrinol Metab 84:3914–3918PubMedGoogle Scholar
  229. Xu WH, Long JR, Zheng W, Ruan ZX, Cai Q, Cheng JR, Xiang YB, Shu XO (2009) Association of the progesterone receptor gene with endometrial cancer risk in a Chinese population. Cancer 115:2693–2700PubMedCentralPubMedGoogle Scholar
  230. Yamazaki H, Shaw PM, Guengerich FP, Shimada T (1998) Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. Chem Res Toxicol 11:659–665PubMedGoogle Scholar
  231. Yan L, Beckman RA (2005) Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development. Biotechniques 39:565–568PubMedGoogle Scholar
  232. Yan L, Shu-Ying Y, Shan K, Yip BH, Rong-Miao Z, Na W, Hai-Yan S (2012) Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy. Pharmacogenomics 13:419–427PubMedGoogle Scholar
  233. Yang X, Dong Y, Zhao J, Sun H, Deng Y, Fan J, Yan Q (2007) Increased expression of human macrophage metalloelastase (MMP-12) is associated with the invasion of endometrial adenocarcinoma. Pathol Res Pract 203:499–505PubMedGoogle Scholar
  234. Yoneda K, Tanji Y, Ikeda N, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S (2002) Influence of adjuvant tamoxifen treatment on bone mineral density and bone turnover markers in postmenopausal breast cancer patients in Japan. Cancer Lett 186:223–230PubMedGoogle Scholar
  235. Yoshimura M, Yasue H, Nakayama M, Shimasaki Y, Sumida H, Sugiyama S, Kugiyama K, Ogawa H, Ogawa Y, Saito Y, Miyamoto Y, Nakao K (1998) A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese. Hum Genet 103:65–69PubMedGoogle Scholar
  236. Yu JJ, Lee KB, Mu C, Li Q, Abernathy TV, Bostick-Bruton F, Reed E (2000) Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 16:555–560PubMedGoogle Scholar
  237. Zhao L, Dewan AT, Bracken MB (2012) Association of maternal AGTR1 polymorphisms and preeclampsia: a systematic review and meta-analysis. J Matern Fetal Neonatal Med 25:2676–2680Google Scholar
  238. zur Hausen H (2000) Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 92:690–698PubMedGoogle Scholar

Copyright information

© Springer India 2013

Authors and Affiliations

  1. 1.University Institute of Engineering and TechnologyPanjab UniversityChandigarhIndia
  2. 2.Biochemistry, Postgraduate Institute of Medical Education and Research (PGIMER)ChandigarhIndia

Personalised recommendations